# Rigel to Present at the Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference
Ticker: RIGL
Company: Rigel Pharmaceuticals
Source: Rigel Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://www.rigel.com
## Summary

, /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president ...

## Article Body
, /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York, NY.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com . Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com .

Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 ir@rigel.com

Media: David Rosen Argot Partners 646.461.6387 david.rosen@argotpartners.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302782544.html

SOURCE Rigel Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-01 12:05 EST — [Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/RIGL/rigel-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-c2f47409) — Source: Rigel Pharmaceuticals
- 2026-06-25 13:46 EST — [Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)](https://biopharmsignal.com/news/RIGL/rigel-announces-closing-of-licensing-agreement-for-veppanutm-vepdegestrant) — Source: Rigel Pharmaceuticals
- 2026-06-25 13:46 EST — [Rigel to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference) — Source: Rigel Pharmaceuticals
- 2026-06-25 13:46 EST — [Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress](https://biopharmsignal.com/news/RIGL/rigel-announces-oral-and-poster-presentations-at-the-2026-asco-annual-meeting-and-eha2026-congress) — Source: Rigel Pharmaceuticals
- 2026-06-25 13:46 EST — [Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-2026-rbc-capital-markets-global-healthcare-conference) — Source: Rigel Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)